Subtype
Colorectal Adenocarcinoma
CI-CAN-00005002Explore in graph →
114 active trials1 approved drugs16 evidence items
Loading cancer entity…
Subtype
CI-CAN-00005002Explore in graph →
Clinical trials
367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (54)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04054752 | Vaccine Response With NT-I7 | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 2, 2023 | clinicaltrials |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT02575508 |
| Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| Roswell Park Cancer InstituteOTHER |
| 1 |
| May 20, 2016 |
| clinicaltrials |
Data updated 22 days agoSource updated Nov 2, 2023source: clinicaltrials